PMID- 9784911
OWN - NLM
STAT- MEDLINE
DCOM- 19981230
LR  - 20190915
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 12
IP  - 3
DP  - 1998 Jul
TI  - Elevation of plasma adenosine levels may attenuate the severity of chronic heart 
      failure.
PG  - 307-9
AB  - Adenosine is known to be an endogenous cardioprotective substance. Since we have 
      reported that adenosine levels increase in patients with chronic heart failure, 
      we tested whether further elevation of the adenosine levels due to dipyridamole 
      or dilazep for 6 months modulates the pathophysiology of chronic heart failure. 
      In patients with chronic heart failure, either dipyridamole (300 mg/d n = 17) or 
      dilazep (300 mg/d n = 5) were administered for 6 months. Twenty-two patients 
      (mean +/- SE age 58 +/- 4 years old) attending a specialized chronic heart 
      failure (CHF) clinic over 6 months and judged as in New York Heart Association 
      (NYHA) function class II or III were examined. The other drugs used for the 
      treatment of CHF were not altered during the study. There were 5 patients with 
      CHF caused by ischemic heart diseases, and 17 patients with either valvular heart 
      diseases or dilated cardiomyopathy. We found that increases in the plasma 
      adenosine levels (202 +/- 34 and 372 +/- 74) nmol/L before and after dipyridamole 
      administration, P < 0.005 ameliorate the severity of CHF (NYHA: 2.1 +/- 0.5 to 
      1.7 +/- 0.2). Both ejection fraction and maximal oxygen consumption increased. 
      These improvements in the severity of chronic heart failure returned to baseline 
      levels 6 months after discontinuation of dipyridamole. Comparable results were 
      obtained in the dilazep protocol. We suggest that the elevation of plasma 
      adenosine levels improves the pathophysiology of CHF.
FAU - Kitakaze, M
AU  - Kitakaze M
AD  - First Department of Medicine, Osaka University School of Medicine, Suita, Japan. 
      Kitakaze@imed1.med.osaka-u.ac.jp
FAU - Minamino, T
AU  - Minamino T
FAU - Node, K
AU  - Node K
FAU - Koretsune, Y
AU  - Koretsune Y
FAU - Komamura, K
AU  - Komamura K
FAU - Funaya, H
AU  - Funaya H
FAU - Kuzuya, T
AU  - Kuzuya T
FAU - Hori, M
AU  - Hori M
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Vasodilator Agents)
RN  - 64ALC7F90C (Dipyridamole)
RN  - F8KLC2BD5Z (Dilazep)
RN  - K72T3FS567 (Adenosine)
SB  - IM
MH  - Adenosine/*blood
MH  - Adult
MH  - Aged
MH  - Cardiac Output, Low/*blood
MH  - Chronic Disease
MH  - Dilazep/therapeutic use
MH  - Dipyridamole/therapeutic use
MH  - Humans
MH  - Middle Aged
MH  - Prognosis
MH  - Vasodilator Agents/therapeutic use
EDAT- 1998/10/24 00:00
MHDA- 1998/10/24 00:01
CRDT- 1998/10/24 00:00
PHST- 1998/10/24 00:00 [pubmed]
PHST- 1998/10/24 00:01 [medline]
PHST- 1998/10/24 00:00 [entrez]
AID - 10.1023/a:1007726018470 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 1998 Jul;12(3):307-9. doi: 10.1023/a:1007726018470.